EUVIMEDEUVIMED entdecken
Open Access

Does Preoperative Bisphosphonate Use Impact the Risk of Periprosthetic Fracture Following Total Hip Arthroplasty?

Rodnell Busigó Torres, James Hong, Hanish Kodali, Jashvant Poeran, Brocha Z Stern, Brett L Hayden, Darwin D Chen, Calin S Moucha

The Journal of Arthroplasty · 2025

DOI: 10.1016/j.arth.2024.08.043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Arthroplasty, 2025. Verfasst von Rodnell Busigó Torres und 7 weiteren Autor:innen. Beteiligte Einrichtung: Leni and Peter W. May Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Hip, Periprosthetic Fractures, Diphosphonates, Bone Density Conservation Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences, Icahn School of Medicine at Mount Sinai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bisphosphonate (BP) use is not uncommon among total hip arthroplasty (THA) candidates. While the impact of BP therapy post-THA has been investigated, there is a paucity of literature discussing the impact of BP therapy pre-THA. Using a national dataset, we aimed to study the association between preoperative BP use and surgical outcomes in primary THA recipients. METHODS: This retrospective cohort study used a commercial claims and Medicare Supplemental database to identify adults aged ≥ 18 years who had an index nonfracture-related primary THA from 2016 to 2020. The use of BP was defined as ≥ 6 months of BP therapy in the year prior to THA. Outcomes were 90-day all-cause readmission, 90-day readmission related to periprosthetic fracture (PPF), 90-day and 1-year all-cause revision, 1-year PPF-related revision, and 1-year diagnosis of PPF. In a 1:5 propensity score-matched analysis, each THA patient who had preoperative BP use was matched to five THA patients who did not have preoperative BP use. Logistic regression models were fitted; we report odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Of 91,907 THA patients, 1,018 (1.1%) used BP preoperatively. In the propensity score-matched cohort (1,018 preoperative BP users and 5,090 controls), preoperative BP use was significantly associated with increased odds of 90-day all-cause revision surgery (OR 1.67; 95% CI 1.10 to 2.53; P = 0.02), 1-year PPF-related revision (OR 2.23; 95% CI 1.21 to 4.10; P = 0.01), and 1-year PPF diagnosis (OR 1.88; 95% CI 1.10 to 3.20; P = 0.02). There were no statistically significant associations between preoperative BP use and the other outcomes in the matched cohort. CONCLUSIONS: These findings suggest that preoperative BP use is associated with an increased risk of revision surgery and PPF in both the short and long term. This information can help in preoperative planning and patient counseling, potentially leading to improved surgical outcomes and reduced complication rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthroplasty, Replacement, HipPeriprosthetic FracturesDiphosphonatesBone Density Conservation AgentsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedReoperationAged, 80 and overRisk FactorsUnited StatesPatient Readmission

Stichwörter der Autor:innen

arthroplastydisphosphonatesosteoporosisperiprosthetic fracturereoperation

Substanzen

DiphosphonatesBone Density Conservation Agents

Autor:innen und Institutionen

  • Leni and Peter W. May Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Leni and Peter W. May Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York; Institute for Healthcare Delivery Science, Department of Population Health Science and Policy, Icahn…

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • Icahn School of Medicine at Mount Sinai

Zitieren

APA

Busigó Torres, R., Hong, J., Kodali, H., Poeran, J., Stern, B. Z., Hayden, B. L., Chen, D. D., & Moucha, C. S. (2025). Does Preoperative Bisphosphonate Use Impact the Risk of Periprosthetic Fracture Following Total Hip Arthroplasty?. The Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2024.08.043

Vancouver

Busigó Torres R, Hong J, Kodali H, Poeran J, Stern BZ, Hayden BL, et al. Does Preoperative Bisphosphonate Use Impact the Risk of Periprosthetic Fracture Following Total Hip Arthroplasty?. The Journal of Arthroplasty. 2025. doi:10.1016/j.arth.2024.08.043

BibTeX
@article{BusigTorres2025,
  author = {Busigó Torres, Rodnell and Hong, James and Kodali, Hanish and Poeran, Jashvant and Stern, Brocha Z and Hayden, Brett L and Chen, Darwin D and Moucha, Calin S},
  title = {Does Preoperative Bisphosphonate Use Impact the Risk of Periprosthetic Fracture Following Total Hip Arthroplasty?},
  journal = {The Journal of Arthroplasty},
  year = {2025},
  doi = {10.1016/j.arth.2024.08.043}
}
Kostenlos starten →